Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Tibotec: "We are excited to be able to study and develop PREZISTA with an alternative boosting agent in a combination product which has the potential to reduce…
POZ characterized the partnership as the first PI-containing complete STR program — meaningful progress on pill-burden reduction, made viable by GS…
FDA approval of Symtuza on 17 July 2018 confirmed the 2011 Gilead-Tibotec STR program delivered the first and only complete darunavir-based single-tablet…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Gilead and Tibotec (J&J) finalized a co-development agreement for a single-tablet HIV regimen pairing Prezista with cobicistat, emtricitabine and GS 7340 (later TAF). Financial terms not disclosed; strategically significant HIV combo deal.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Tibotec Pharmaceuticals (Janssen) (this deal) | 2011 | — | — |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2011 deals · Gilead Sciences Inc. deals · Infectious Disease deals